FDA Extends Review for Biogen’s Subcutaneous Lecanemab Dosing by Three Months
Event summary
- FDA extends review period for Biogen’s LEQEMBI® IQLIK™ subcutaneous injection by three months, setting new PDUFA action date to August 24, 2026.
- Request for additional information constitutes a major amendment to the sBLA, delaying approval timeline.
- LEQEMBI has already been approved in over 50 regulatory authorities worldwide for early Alzheimer’s treatment.
- Subcutaneous formulation aims to provide greater flexibility and choice in anti-amyloid treatment delivery.
The big picture
The extension of the FDA review period for LEQEMBI® IQLIK™ highlights the regulatory scrutiny faced by novel Alzheimer’s treatments. Biogen and Eisai’s collaboration on lecanemab underscores the strategic importance of subcutaneous formulations in expanding treatment options. The broader industry trend towards flexible dosing regimens aims to improve patient compliance and accessibility, potentially reshaping the competitive dynamics in neurodegenerative disease therapy.
What we're watching
- Regulatory Dynamics
- How the FDA’s request for additional information will impact the approval timeline and Biogen’s strategic planning.
- Market Positioning
- Whether the subcutaneous formulation can enhance LEQEMBI’s competitive edge in the Alzheimer’s treatment landscape.
- Clinical Efficacy
- The pace at which Biogen and Eisai can address ARIA risks and other safety concerns to ensure long-term patient adoption.
Related topics